Heparin-induced thrombocytopenia: Principles for early recognition and management

Article Type

Article

Changed

Tue, 09/25/2018 - 11:07

Display Headline

Heparin-induced thrombocytopenia: Principles for early recognition and management

Author(s)

John R. Bartholomew, MD

Susan M. Begelman, MD

Amjad AlMahameed, MD, MPH, FACP

Article PDF

content_72_Suppl_1_SI-31.pdf

Author and Disclosure Information

John R. Bartholomew, MD
Section of Vascular Medicine, Department of Cardiovascular Medicine and the Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, Ohio

Susan M. Begelman, MD
Section of Vascular Medicine, Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio

Amjad AlMahameed, MD
Section of Vascular Medicine, Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio

Correspondence: John R. Bartholomew, MD, Section of Vascular Medicine, S60, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

Dr. Bartholomew is a consultant for The Medicines Company and on the speakers' bureau of GlaxoSmithKline.

Dr. Begelman is a consultant for and on the speakers' bureau of GlaxoSmithKline.

Dr. AlMahameed has indicated that he has nothing to disclose.

Publications

Cleveland Clinic Journal of Medicine

Page Number

S31-S36

Author(s)

John R. Bartholomew, MD

Susan M. Begelman, MD

Amjad AlMahameed, MD, MPH, FACP

Author(s)

John R. Bartholomew, MD

Susan M. Begelman, MD

Amjad AlMahameed, MD, MPH, FACP

Author and Disclosure Information

John R. Bartholomew, MD
Section of Vascular Medicine, Department of Cardiovascular Medicine and the Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, Ohio

Susan M. Begelman, MD
Section of Vascular Medicine, Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio

Amjad AlMahameed, MD
Section of Vascular Medicine, Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio

Correspondence: John R. Bartholomew, MD, Section of Vascular Medicine, S60, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

Dr. Bartholomew is a consultant for The Medicines Company and on the speakers' bureau of GlaxoSmithKline.

Dr. Begelman is a consultant for and on the speakers' bureau of GlaxoSmithKline.

Dr. AlMahameed has indicated that he has nothing to disclose.

Author and Disclosure Information

John R. Bartholomew, MD
Section of Vascular Medicine, Department of Cardiovascular Medicine and the Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, Ohio

Susan M. Begelman, MD
Section of Vascular Medicine, Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio

Amjad AlMahameed, MD
Section of Vascular Medicine, Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio

Correspondence: John R. Bartholomew, MD, Section of Vascular Medicine, S60, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

Dr. Bartholomew is a consultant for The Medicines Company and on the speakers' bureau of GlaxoSmithKline.

Dr. Begelman is a consultant for and on the speakers' bureau of GlaxoSmithKline.

Dr. AlMahameed has indicated that he has nothing to disclose.

Article PDF

content_72_Suppl_1_SI-31.pdf

Article PDF

content_72_Suppl_1_SI-31.pdf

Page Number

S31-S36

Page Number

S31-S36

Publications